Xenon Reports Phase 1 and Preclinical Data for Acute-Pain Programs
Xenon said the data support advancing XEN1701 and XEN1120 to Phase 2 proof-of-concept studies.
Related stories
Vamos Q3 net profit at 151 million reais
Vamos reported Q3 net profit of 151 million reais, versus the IBES estimate of 134 million reais.
M impact | EQUITY | Oct 29, 2026, 11:18 PM UTC
Glaukos Raises 2026 Net Sales Guidance to $77
Glaukos raised its 2026 net sales guidance to $77; the supplied text provides no unit or further details.
M impact | EQUITY | Oct 29, 2026, 11:17 PM UTC
Pebblebrook Hotel Trust Reports Quarterly Results
Pebblebrook Hotel Trust reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:16 PM UTC
Banco del Bajío Publishes Q3 2026 Earnings Call Transcript
Banco del Bajío published a transcript of its Q3 2026 earnings call.
M impact | EQUITY | Oct 29, 2026, 11:16 PM UTC
World Kinect Reports Quarterly Results for Period Ended September 30
M impact | EQUITY | Oct 29, 2026, 11:15 PM UTC
Strattec Security Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 11:14 PM UTC